02Jan 2024
Cyclosporin and Ustekinumab Combination Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis

Cyclosporin and Ustekinumab Combination Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis

In addressing the challenge of managing acute severe ulcerative colitis (ASUC) post-cyclosporin therapy, this prospective, monocentric study explored the efficacy and safety of a combination of cyclosporin and ustekinumab in patients with steroid-refractory ASUC. Among 11 patients with prior treatment failures, the combination achieved clinical and endoscopic remission in almost half after 52 weeks. Despite two colectomies and three discontinuations due to ineffectiveness, the therapy demonstrated overall good tolerance. These promising results support the need for further investigations into this combined approach for ASUC management.

  • #gastroenterology

Like

Save

Share